List of Tables
Table 1. Global Nucleic Acid-based Therapy Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Nucleic Acid-based Therapy Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Nucleic Acid-based Therapy Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Nucleic Acid-based Therapy Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Nucleic Acid-based Therapy Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Nucleic Acid-based Therapy Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Nucleic Acid-based Therapy Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Nucleic Acid-based Therapy by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nucleic Acid-based Therapy as of 2024)
Table 11. Global Nucleic Acid-based Therapy Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Nucleic Acid-based Therapy Companies Headquarters
Table 13. Global Nucleic Acid-based Therapy Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Nucleic Acid-based Therapy Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Nucleic Acid-based Therapy Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Nucleic Acid-based Therapy Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Nucleic Acid-based Therapy Revenue by Application (2026-2031) & (US$ Million)
Table 21. Nucleic Acid-based Therapy High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Nucleic Acid-based Therapy Growth Accelerators and Market Barriers
Table 25. North America Nucleic Acid-based Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Nucleic Acid-based Therapy Growth Accelerators and Market Barriers
Table 27. Europe Nucleic Acid-based Therapy Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Nucleic Acid-based Therapy Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Nucleic Acid-based Therapy Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Nucleic Acid-based Therapy Investment Opportunities and Key Challenges
Table 31. Central and South America Nucleic Acid-based Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Nucleic Acid-based Therapy Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Nucleic Acid-based Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Sarepta Therapeutics Corporation Information
Table 35. Sarepta Therapeutics Description and Major Businesses
Table 36. Sarepta Therapeutics Product Features and Attributes
Table 37. Sarepta Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Sarepta Therapeutics Revenue Proportion by Product in 2024
Table 39. Sarepta Therapeutics Revenue Proportion by Application in 2024
Table 40. Sarepta Therapeutics Revenue Proportion by Geographic Area in 2024
Table 41. Sarepta Therapeutics Nucleic Acid-based Therapy SWOT Analysis
Table 42. Sarepta Therapeutics Recent Developments
Table 43. Ionis Pharmaceuticals Corporation Information
Table 44. Ionis Pharmaceuticals Description and Major Businesses
Table 45. Ionis Pharmaceuticals Product Features and Attributes
Table 46. Ionis Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Ionis Pharmaceuticals Revenue Proportion by Product in 2024
Table 48. Ionis Pharmaceuticals Revenue Proportion by Application in 2024
Table 49. Ionis Pharmaceuticals Revenue Proportion by Geographic Area in 2024
Table 50. Ionis Pharmaceuticals Nucleic Acid-based Therapy SWOT Analysis
Table 51. Ionis Pharmaceuticals Recent Developments
Table 52. Alnylam Corporation Information
Table 53. Alnylam Description and Major Businesses
Table 54. Alnylam Product Features and Attributes
Table 55. Alnylam Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Alnylam Revenue Proportion by Product in 2024
Table 57. Alnylam Revenue Proportion by Application in 2024
Table 58. Alnylam Revenue Proportion by Geographic Area in 2024
Table 59. Alnylam Nucleic Acid-based Therapy SWOT Analysis
Table 60. Alnylam Recent Developments
Table 61. Biogen Corporation Information
Table 62. Biogen Description and Major Businesses
Table 63. Biogen Product Features and Attributes
Table 64. Biogen Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Biogen Revenue Proportion by Product in 2024
Table 66. Biogen Revenue Proportion by Application in 2024
Table 67. Biogen Revenue Proportion by Geographic Area in 2024
Table 68. Biogen Nucleic Acid-based Therapy SWOT Analysis
Table 69. Biogen Recent Developments
Table 70. Nippon Shinyaku Corporation Information
Table 71. Nippon Shinyaku Description and Major Businesses
Table 72. Nippon Shinyaku Product Features and Attributes
Table 73. Nippon Shinyaku Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Nippon Shinyaku Revenue Proportion by Product in 2024
Table 75. Nippon Shinyaku Revenue Proportion by Application in 2024
Table 76. Nippon Shinyaku Revenue Proportion by Geographic Area in 2024
Table 77. Nippon Shinyaku Nucleic Acid-based Therapy SWOT Analysis
Table 78. Nippon Shinyaku Recent Developments
Table 79. Sobi Corporation Information
Table 80. Sobi Description and Major Businesses
Table 81. Sobi Product Features and Attributes
Table 82. Sobi Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Sobi Recent Developments
Table 84. Novartis Corporation Information
Table 85. Novartis Description and Major Businesses
Table 86. Novartis Product Features and Attributes
Table 87. Novartis Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Novartis Recent Developments
Table 89. BioNTech Corporation Information
Table 90. BioNTech Description and Major Businesses
Table 91. BioNTech Product Features and Attributes
Table 92. BioNTech Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. BioNTech Recent Developments
Table 94. Pfizer Corporation Information
Table 95. Pfizer Description and Major Businesses
Table 96. Pfizer Product Features and Attributes
Table 97. Pfizer Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Pfizer Recent Developments
Table 99. Moderna Therapeutics Corporation Information
Table 100. Moderna Therapeutics Description and Major Businesses
Table 101. Moderna Therapeutics Product Features and Attributes
Table 102. Moderna Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Moderna Therapeutics Recent Developments
Table 104. Jazz Pharmaceuticals Corporation Information
Table 105. Jazz Pharmaceuticals Description and Major Businesses
Table 106. Jazz Pharmaceuticals Product Features and Attributes
Table 107. Jazz Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Jazz Pharmaceuticals Recent Developments
Table 109. CureVac Corporation Information
Table 110. CureVac Description and Major Businesses
Table 111. CureVac Product Features and Attributes
Table 112. CureVac Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. CureVac Recent Developments
Table 114. Regulus Therapeutics Corporation Information
Table 115. Regulus Therapeutics Description and Major Businesses
Table 116. Regulus Therapeutics Product Features and Attributes
Table 117. Regulus Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. Regulus Therapeutics Recent Developments
Table 119. ProQR Corporation Information
Table 120. ProQR Description and Major Businesses
Table 121. ProQR Product Features and Attributes
Table 122. ProQR Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. ProQR Recent Developments
Table 124. Secarna Corporation Information
Table 125. Secarna Description and Major Businesses
Table 126. Secarna Product Features and Attributes
Table 127. Secarna Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. Secarna Recent Developments
Table 129. MiNA Therapeutics Corporation Information
Table 130. MiNA Therapeutics Description and Major Businesses
Table 131. MiNA Therapeutics Product Features and Attributes
Table 132. MiNA Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 133. MiNA Therapeutics Recent Developments
Table 134. Sylentis Corporation Information
Table 135. Sylentis Description and Major Businesses
Table 136. Sylentis Product Features and Attributes
Table 137. Sylentis Revenue (US$ Million) and Gross Margin (2020-2025)
Table 138. Sylentis Recent Developments
Table 139. Arrowhead Corporation Information
Table 140. Arrowhead Description and Major Businesses
Table 141. Arrowhead Product Features and Attributes
Table 142. Arrowhead Revenue (US$ Million) and Gross Margin (2020-2025)
Table 143. Arrowhead Recent Developments
Table 144. Silence Therapeutics Corporation Information
Table 145. Silence Therapeutics Description and Major Businesses
Table 146. Silence Therapeutics Product Features and Attributes
Table 147. Silence Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 148. Silence Therapeutics Recent Developments
Table 149. Dicerna Corporation Information
Table 150. Dicerna Description and Major Businesses
Table 151. Dicerna Product Features and Attributes
Table 152. Dicerna Revenue (US$ Million) and Gross Margin (2020-2025)
Table 153. Dicerna Recent Developments
Table 154. Raw Materials Key Suppliers
Table 155. Distributors List
Table 156. Market Trends and Market Evolution
Table 157. Market Drivers and Opportunities
Table 158. Market Challenges, Risks, and Restraints
Table 159. Research Programs/Design for This Report
Table 160. Key Data Information from Secondary Sources
Table 161. Key Data Information from Primary Sources
List of Figures
Figure 1. Nucleic Acid-based Therapy Product Picture
Figure 2. Global Nucleic Acid-based Therapy Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Antisense Oligonucleotides (ASO) Product Picture
Figure 4. siRNA Product Picture
Figure 5. mRNA Product Picture
Figure 6. Global Nucleic Acid-based Therapy Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Neuromuscular Diseases
Figure 8. hATTR
Figure 9. COVID-19
Figure 10. Other
Figure 11. Nucleic Acid-based Therapy Report Years Considered
Figure 12. Global Nucleic Acid-based Therapy Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Nucleic Acid-based Therapy Revenue (2020-2031) & (US$ Million)
Figure 14. Global Nucleic Acid-based Therapy Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Nucleic Acid-based Therapy Revenue Market Share by Region (2020-2031)
Figure 16. Global Nucleic Acid-based Therapy Revenue Market Share Ranking (2024)
Figure 17. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 18. Antisense Oligonucleotides (ASO) Revenue Market Share by Player in 2024
Figure 19. siRNA Revenue Market Share by Player in 2024
Figure 20. mRNA Revenue Market Share by Player in 2024
Figure 21. Global Nucleic Acid-based Therapy Revenue Market Share by Type (2020-2031)
Figure 22. Global Nucleic Acid-based Therapy Revenue Market Share by Application (2020-2031)
Figure 23. North America Nucleic Acid-based Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 24. North America Top 5 Players Nucleic Acid-based Therapy Revenue (US$ Million) in 2024
Figure 25. North America Nucleic Acid-based Therapy Revenue (US$ Million) by Type (2020 - 2031)
Figure 26. North America Nucleic Acid-based Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 27. US Nucleic Acid-based Therapy Revenue (2020-2031) & (US$ Million)
Figure 28. Canada Nucleic Acid-based Therapy Revenue (2020-2031) & (US$ Million)
Figure 29. Mexico Nucleic Acid-based Therapy Revenue (2020-2031) & (US$ Million)
Figure 30. Europe Nucleic Acid-based Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 31. Europe Top 5 Players Nucleic Acid-based Therapy Revenue (US$ Million) in 2024
Figure 32. Europe Nucleic Acid-based Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 33. Europe Nucleic Acid-based Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 34. Germany Nucleic Acid-based Therapy Revenue (2020-2031) & (US$ Million)
Figure 35. France Nucleic Acid-based Therapy Revenue (2020-2031) & (US$ Million)
Figure 36. U.K. Nucleic Acid-based Therapy Revenue (2020-2031) & (US$ Million)
Figure 37. Italy Nucleic Acid-based Therapy Revenue (2020-2031) & (US$ Million)
Figure 38. Russia Nucleic Acid-based Therapy Revenue (2020-2031) & (US$ Million)
Figure 39. Asia-Pacific Nucleic Acid-based Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 40. Asia-Pacific Top 8 Players Nucleic Acid-based Therapy Revenue (US$ Million) in 2024
Figure 41. Asia-Pacific Nucleic Acid-based Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 42. Asia-Pacific Nucleic Acid-based Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 43. Indonesia Nucleic Acid-based Therapy Revenue (2020-2031) & (US$ Million)
Figure 44. Japan Nucleic Acid-based Therapy Revenue (2020-2031) & (US$ Million)
Figure 45. South Korea Nucleic Acid-based Therapy Revenue (2020-2031) & (US$ Million)
Figure 46. Australia Nucleic Acid-based Therapy Revenue (2020-2031) & (US$ Million)
Figure 47. India Nucleic Acid-based Therapy Revenue (2020-2031) & (US$ Million)
Figure 48. Indonesia Nucleic Acid-based Therapy Revenue (2020-2031) & (US$ Million)
Figure 49. Vietnam Nucleic Acid-based Therapy Revenue (2020-2031) & (US$ Million)
Figure 50. Malaysia Nucleic Acid-based Therapy Revenue (2020-2031) & (US$ Million)
Figure 51. Philippines Nucleic Acid-based Therapy Revenue (2020-2031) & (US$ Million)
Figure 52. Singapore Nucleic Acid-based Therapy Revenue (2020-2031) & (US$ Million)
Figure 53. Central and South America Nucleic Acid-based Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 54. Central and South America Top 5 Players Nucleic Acid-based Therapy Revenue (US$ Million) in 2024
Figure 55. Central and South America Nucleic Acid-based Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 56. Central and South America Nucleic Acid-based Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 57. Brazil Nucleic Acid-based Therapy Revenue (2020-2025) & (US$ Million)
Figure 58. Argentina Nucleic Acid-based Therapy Revenue (2020-2025) & (US$ Million)
Figure 59. Middle East and Africa Nucleic Acid-based Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 60. Middle East and Africa Top 5 Players Nucleic Acid-based Therapy Revenue (US$ Million) in 2024
Figure 61. South America Nucleic Acid-based Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 62. Middle East and Africa Nucleic Acid-based Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 63. GCC Countries Nucleic Acid-based Therapy Revenue (2020-2025) & (US$ Million)
Figure 64. Israel Nucleic Acid-based Therapy Revenue (2020-2025) & (US$ Million)
Figure 65. Egypt Nucleic Acid-based Therapy Revenue (2020-2025) & (US$ Million)
Figure 66. South Africa Nucleic Acid-based Therapy Revenue (2020-2025) & (US$ Million)
Figure 67. Nucleic Acid-based Therapy Industry Chain Mapping
Figure 68. Channels of Distribution (Direct Vs Distribution)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
